Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
独立董事2023年度述职报告（沈永建）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company, covering the director's activities, attendance at board and committee meetings, opinions on company matters, communication with auditors and shareholders, and overall evaluation for the year 2023. It includes references to the company's annual report, quarterly reports, internal control reports, and audit activities, but it is not the financial report itself. Instead, it is a governance-related report focusing on the independent director's duties and oversight. This fits best under Board/Management Information (MANG), as it relates to board activities and management oversight rather than financial results or audit reports. The document length is 4680 characters, which is substantial and contains detailed content, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-29 Chinese
金陵药业股份有限公司独立董事专门会议议事规则
Governance Information Classification · 95% confidence The document is titled as the 'Rules of Procedure for the Independent Directors' Special Meeting' of Jinling Pharmaceutical Co., Ltd., approved by the board on April 26, 2024. It details governance procedures, meeting composition, responsibilities, voting rules, and record-keeping for independent directors' meetings. There is no financial data, no report of financial results, no announcement of voting outcomes, no executive changes, no legal proceedings, no capital updates, and no regulatory filings. The content focuses on internal governance rules and board structure related to independent directors. This matches the definition of Governance Information (CGR), which covers internal rules and governance practices. The document length is 1618 characters, which is consistent with a governance policy document rather than a full report or announcement.
2024-04-29 Chinese
关于公司子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of its subsidiary's use of idle funds to purchase wealth management products. It details the amounts, dates, and types of financial products purchased, risk disclosures, and risk control measures. The document is relatively short (3017 characters) and focuses on a specific financing activity related to cash management and investment of idle funds. It does not contain comprehensive financial statements or quarterly/yearly financial results, nor is it a report or transcript. It is an update on capital usage and financing activities. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP).
2024-04-29 Chinese
金陵药业股份有限公司2023年度财务决算报告
Annual Report Classification · 100% confidence The document is titled as the company's 2023 annual financial settlement report and includes detailed financial statements, accounting policy changes, asset and liability analysis, profit and loss analysis, and other comprehensive financial data for the full fiscal year 2023. It also mentions an audit report issued by an accounting firm, confirming the financial statements' compliance and fairness. The length of the document (7775 characters) and the detailed financial content indicate this is the full annual report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-29 Chinese
董事会对独立董事独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors for the year 2023. It references regulatory guidelines about independent directors and their qualifications. The content is focused on governance and compliance with independence requirements rather than financial data or report publication. The document length is short (679 characters) and it is a formal statement about board/management matters, specifically about independent directors' independence evaluation. This fits best under Board/Management Information (MANG) as it concerns board composition and director qualifications.
2024-04-29 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders. The document does not contain financial statements or results but rather logistical and procedural details for the AGM. The document length is 4384 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM.
2024-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.